antiepileptic drugs: phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
Study summary
The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.
Eligibility
Sex
ALL
Min age
65 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥65 years old;
2. Diagnosed with epilepsy;
3. Using antiepileptic drugs for treatment;
Exclusion Criteria:
1. Patients who are expected to die within 48 hours;
2. Patients with allergy to antiepileptic drugs;
3. Patients receiving other investigational drugs;
4. Other factors that the researcher considers unsuitable for inclusion.
Primary outcome measure(s)
The peak plasma drug concentration of antiepileptic drugs. — at (0-4) h after oral administration To detect the peak plasma drug concentration of antiepileptic drugs.
The random plasma drug concentration of antiepileptic drugs. — at (4-10) h after oral administration To detect the random plasma drug concentration of antiepileptic drugs.
The trough plasma drug concentration of antiepileptic drugs. — at (1-2) h before the next administration To detect the trough plasma drug concentration of antiepileptic drugs.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.